Quantcast
Last updated on April 21, 2014 at 9:22 EDT

Latest OncoSec Medical Inc. Stories

2013-03-25 08:26:15

45 percent of Treated Lesions Demonstrated a Durable Response Of At Least 6 Months SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) - a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors - announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies...

2013-03-18 08:28:01

SAN DIEGO, March 18, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced Dr. Adil Daud, chair of OncoSec's Melanoma Advisory Board, will present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Hilton New York Hotel on Friday, March 22 at 2:25 PM ET. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Dr. Daud will...

2013-03-14 08:28:10

SAN DIEGO, March 14, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the 25(th) Annual Roth Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California, on Tuesday, March 19th at 8:00AM Pacific Time. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Mr. Dhillon will...

2013-02-26 08:28:10

Thought-Leaders to Steer Development of the Company's ImmunoPulse Program SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the formation of a Melanoma Advisory Board (MAB) for the company's metastatic melanoma program. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Bringing together a group of...

2013-02-19 08:31:34

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Vice President and Controller, Veronica Vallejo has been promoted to Chief Financial Officer effective February 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) "Veronica has been an integral part of our team since the inception of OncoSec and this...

2013-02-06 08:26:03

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the 15(th) Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City, on Tuesday, February 12th at 3:00PM Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) ABOUT THE BIO CEO...

2013-01-17 08:25:55

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the Noble Financial Capital Markets' Ninth Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22 at 12:30 PM Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)...

2013-01-15 07:17:10

SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the company's upcoming milestones for 2013 at the Biotech Showcase conference held January 7-9 in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) "2012 marked a critical year for OncoSec," said Punit Dhillon, President and CEO. "We launched three...

2013-01-03 08:24:57

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will provide a corporate update and outline of anticipated 2013 milestones at Biotech Showcase 2013 on Tuesday, January 8 at 3:45 pm PT. The presentation will be held in Room Mission II (Track C) at the Parc 55 Wyndham San Francisco-Union...

2012-12-04 08:28:02

SAN DIEGO, Dec. 04, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) The Company will conduct two presentations...